JUN 1 5 2004

K040617 1 of 2

Reliant Technologies, Inc.
Reliant Laser System II
510(k) Premarket Notification

510(k) SUMMARY

As required by Section 12 of the Medical Devices Act of 1990, Reliant technologies, Inc. is providing a summary of safety and effectiveness information available for Reliant Technologies, Inc. Laser System, as well as the substantial equivalence decision making process.

Submitter:	Reliant Technologies, Inc.
Address:	260 Sheridan Ave. Suite 309 Palo Alto, CA 94306
Contact Person:	Heather Tanner Clinical and Regulatory Affairs
Telephone:	(650) 473-0200 ext. 103
Facsimile:	(650) 473-0357
Date prepared:	March 5, 2004
Device Trade Name:	Reliant Laser System II
Common Name:	Dermatology Laser
Classification Name:	Laser Surgical Instrument 21 C.F.R § 878.4810
Legally Marketed Predicate Devices:	-Reliant Laser System K031795 -Altus Medical CoolGuide Lasers w/Pulsed Light Handpiece K023954 -Aramis II Dermatological Laser K023734 -Candela Smoothbeam Laser System K030846 -Candela YAG Family of Lasers K033172 -Lumenis Ultrapulse Encore Laser, K022060

Description of the Reliant Laser System II:

The Reliant Laser System II consists of a set of fiber lasers, controlled by an embedded processor, to be used in dermatology. The laser system uses scanning and focusing optics to deliver a pattern of thermal energy to the epidermis and upper dermis. Device accessories include tip attachments and pre-treatment solution.

K040617 2 of 2

Indications for use of Reliant Laser System II:

The Reliant Laser System II is intended for:

Dermatological procedures requiring the coagulation of soft tissue;

Treatment of periorbital wrinkles;

Photocoagulation of pigmented lesions, such as, but not limited to lentigos (age spots), solar lentigos (sun spots) and dyschromia.

Performance Standards:

As a laser product, the Reliant Laser System II is required to conform and does conform to the Laser Performance Standard (21 CFR).

SUBSTANTIAL EQUIVALENCE COMPARISON

The technological characteristics and indications for use of the Reliant Laser System II are similar to those of the cited predicate laser devices. These devices are equivalent in terms of design, materials, principal of operation, and product specifications. Any differences between the Reliant Technologies Laser System II and the predicate devices do not raise new issues regarding safety or effectiveness.

Clinical Performance Data

Results of clinical evaluations were used to demonstrate that the Reliant Technologies Laser System II functioned as clinically intended. Sufficient data have been gathered from clinical studies to determine that the Reliant Laser System II performs as clinically intended and that no new issues of safety and effectiveness are introduced.

CONCLUSION

Based on the design, materials, function, intended use, and clinical evaluation, the Reliant Technologies Laser System II is substantially equivalent to the devices currently marketed under the Federal Food, Drug and Cosmetic Act. In addition, the Reliant Technologies Laser System II raises no new safety or effectiveness issues. Therefore, safety and effectiveness are reasonably assured, justifying 510(k) clearance for commercial sale.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JUN 1 5 2004

Ms. Heather Tanner
Clinical and Regulatory Affairs
Reliant Technologies, Inc.
260 Sheridan Avenue, Suite 309
Palo Alto, California 94306

Re: K040617
Trade/Device Name: Reliant Laser System II
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology
Regulatory Class: II
Product Code: GEX
Dated: May 5, 2004
Received: May 6, 2004

Dear Ms. Tanner:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Miriam C. Provost

for Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): K040617

Device Name: Reliant Technologies Laser System II

Indications For Use:

The Reliant Technologies Laser System II is intended for:

-Dermatological procedures requiring the coagulation of soft tissue;

-Treatment of periorbital wrinkles;

-Photocoagulation of pigmented lesions, such as, but not limited to lentigos (age spots), solar lentigos (sun spots) and dyschromia.

Prescription Use ___X___ (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use _____ (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Miriam C. Provost

(Division Sign-Off)
Division of General, Restorative, and Neurological Devices

510(k) Number K040617